

SUPPLEMENTAL Form PTO-1449				Attorney's Docket No. 13265-1247 C6		Application Serial No. 603503	
INFORMATION DISCLOSURE STATEMENT				Applicant(s) John J. NESTOR, Jr., et al.			
(use several sheets if necessary)				Filing Date: June 24, 2003		Group Art Unit: To be Assigned	

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
NB NB NB	1.*	10/1982	4,355,032	Verheyden, et al.	424	253	
	2.*	8/1991	5,043,339	Beauchamp, Lilia M.	514	274	
	3.*	7/2000	6,083,953	Nestor, et al.	544	276	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation	
							YES	NO
NB NB NB NB NB NB NB NB NB NB NB NB	4.*	6/1978	1 523 865	Great Britain				
	5.*	3/1983	2 104 070	Great Britain				
	6.*	1/1984	2 122 618	Great Britain				
	7.*	6/1990	8829571	Great Britain (application)				
	8.*	10/1985	0 158 847	Europe				
	9.*	7/1986	0 187 297	Europe				
	10.*	12/1987	0 249 248	Europe				
	11.*	3/1989	0 308 065	Europe				
	12.*	6/1990	0 375 329	Europe				
	13.*	12/1994	WO 94/29311	PCT				

OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)		
Examiner Initials	Ref. No.	Title
NB NB NB NB NB NB NB NB NB NB NB	14.*	L.M. Beauchamp, et al., "Amino Acid Ester Prodrugs of Acyclovir", <i>Antiviral Chemistry & Chemotherapy</i> - 3(3):157-164 (1992)
	15.*	Bodanszky, "Principles of Peptide Synthesis, 2 nd edition (Springer-Verlag) pages 9-11
	16.*	L. Colla, et al., "Synthesis and Antiviral Activity of Water-Soluble Esters of Acyclovir...", <i>J. Med. Chem.</i> - 26:602-604 (1983)
	17.*	Crumpacker, <i>New England Journal of Medicine</i> 335, 10, 721-727 (1996)
	18.*	E. Jensen, et al., "Synthesis, Enzymatic Hydrolysis and Physico-Chemical Properties...", <i>Acta Pharm. Nord.</i> - 3(4):243-247 (1991)
	19.*	J.C. Martin, et al., "Synthesis and Antiviral Activity of Various Esters...", <i>J. Pharm. Sci.</i> - 76(2):180-184 (1987)
	20.*	P.C. Maudgal, et al., "Topical Treatment of Experimental Herpes Simplex Keratouveitis...", <i>Arch. Ophthalmol.</i> - 102:140-142 (1984)
	21.*	Merck Index, 13 th ed., page 29
		"NDA Approvals for Calendar Year 2001" from the U.S.
		Food and Drug Administration Center for Drug Evaluation and Research, obtained from the web at http://www.fda.gov/cder/rdmt/ndaaps01cy.htm (4 pages).

EXAMINER: <u>Mann Bu</u>	DATE CONSIDERED: <u>3/11/01</u>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120; 37 C.F.R. §1.98 (d).	